TMCnet News

Research and Markets: Global Anaplastic Large Cell Lymphoma (ALCL) Pipeline Review 2015 - 8 Companies & 14 Drug Profiles
[October 05, 2015]

Research and Markets: Global Anaplastic Large Cell Lymphoma (ALCL) Pipeline Review 2015 - 8 Companies & 14 Drug Profiles


Research and Markets (http://www.researchandmarkets.com/research/szjlcs/anaplastic_large) has announced the addition of the "Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and special featureson late-stage and discontinued projects.



The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development


  • Akron Molecules AG
  • AstraZeneca Plc
  • Bayer AG
  • Celon Pharma Sp. z o.o.
  • Pfizer Inc.
  • Sareum Holdings Plc
  • Seattle Genetics, Inc.
  • Teva Pharmaceutical Industries Limited

Drug Profiles

  • AdIL-24
  • AKR-302
  • AKR-303
  • AZD-3463
  • brentuximab vedotin
  • CEP-28122
  • CEP-37440
  • copanlisib hydrochloride
  • crizotinib
  • Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma
  • KRA-0008
  • SH-7129
  • Small Molecules to Inhibit Aurora and ALK Kinase for Oncology
  • Small Molecules to Inhibit Aurora Kinase and FLT3 Kinase for Oncology

For more information visit http://www.researchandmarkets.com/research/szjlcs/anaplastic_large


[ Back To TMCnet.com's Homepage ]